Genetic testing in kidney transplantation and living kidney donor risk assessment
Kidney International · 2026-07 · 110 (1) · 190-205
DOI: 10.1016/j.kint.2026.02.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026-07. Verfasst von Clara Schott und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. Hauptthemen laut MEDLINE: Kidney Transplantation, Living Donors, Genetic Testing, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis, Schulich School of Medicine and Dentistry Department of Family Medicine, Western University.
Abstract (Originalsprache)
INTRODUCTION: The cause of kidney failure in kidney transplant recipients remains unknown in 20-45% of cases. Outcomes for living kidney donors (LKDs) are generally excellent, with only 8% experiencing complications post-donation. Here, we hypothesize that genetic testing could identify a genetic etiology in at least 20% of recipients and inform risk stratification in LKDs. METHODS: Genetic testing was performed in 231 transplant recipients and 46 prospective LKDs by means of exome sequencing of 409 chronic kidney disease (CKD)-associated genes. We also assessed 122 retrospective LKDs who developed adverse kidney outcomes post-donation which were defined by at least two of the three criteria: hypertension, a glomerular filtration rate under 60 mL/min/1.73m2, or a urine albumin to creatinine ratio of 3 mg/mmol or more. RESULTS: Pathogenic or likely pathogenic (P/LP) variants were identified in 23% of recipients, most commonly involving genes associated with cystic kidney disease and glomerulopathies. Among the recipients with a genetic diagnosis, there was a 37% rate of reclassification to a different phenotype post genetic testing. Among prospective LKDs, 4% had P/LP variants. In the retrospective cohort of LKDs with adverse kidney outcomes post donation, 19% carried P/LP variants. CONCLUSIONS: Genetic testing yielded a high diagnostic rate and frequently reclassified CKD etiology in transplant recipients, underscoring its diagnostic utility. Universal genetic testing of asymptomatic LKDs had a yield of 4%, although our prospective LKD cohort had limited sample size. In contrast, high proportion of LKDs with adverse kidney outcome post-donation were found to carry P/LP variants in CKD-associated genes. Our findings suggest that targeted genetic testing of high-risk donors may be a preferred over universal testing strategy to optimize donor selection in LKDs. However, further evaluation is warranted to ensure this approach appropriately balances donor safety with equitable access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada.
- Division of Nephrology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.
- Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
- Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
- London Health Sciences Centre, London, Ontario, Canada.
- Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada.
Förderung
- Novartis
- Schulich School of Medicine and Dentistry Department of Family Medicine
- Western University
- AMOSO
- Lawson Health Research Institute
- Canadian Institutes of Health Research
Zitieren
APA
Schott, C., Relouw, S., Arnaldi, M., Baker, C., Offerni-Almada, G., Wang, J., McIntyre, A. D., Son, S., Cuerden, M., Arnold, J. B., Burman, N., Colaiacovo, S., Solo, K., Boudville, N., Dipchand, C., Feldman, L. S., Gill, J., Gunaratnam, L., House, A. A., …, & Connaughton, D. M. (2026). Genetic testing in kidney transplantation and living kidney donor risk assessment. Kidney International, 110(1), 190-205. https://doi.org/10.1016/j.kint.2026.02.033
Vancouver
Schott C, Relouw S, Arnaldi M, Baker C, Offerni-Almada G, Wang J, et al. Genetic testing in kidney transplantation and living kidney donor risk assessment. Kidney International. 2026;110(1):190-205. doi:10.1016/j.kint.2026.02.033
BibTeX
@article{Schott2026,
author = {Schott, Clara and Relouw, Sydney and Arnaldi, Monica and Baker, Cadence and Offerni-Almada, Gabriela and Wang, Jian and McIntyre, Adam D and Son, Surim and Cuerden, Meaghan and Arnold, Jennifer B and Burman, Nikita and Colaiacovo, Samantha and Solo, Karla and Boudville, Neil and Dipchand, Christine and Feldman, Liane S and Gill, John and Gunaratnam, Lakshman and House, Andrew A and Iyer, Hariharan and Johnson, John and Karpinski, Martin and Klarenbach, Scott and Knoll, Greg and Lok, Charmaine E and Lotfy, Khaled and Miller, Matthew and Monroy-Cuadros, Mauricio and Nguan, Christopher and Rehman, Faisal and Roshanov, Pavel S and Prasad, G V Ramesh and Storsley, Leroy and Weir, Matthew A and Hegele, Robert A and Garg, Amit X and Connaughton, Dervla M},
title = {Genetic testing in kidney transplantation and living kidney donor risk assessment},
journal = {Kidney International},
year = {2026},
volume = {110},
number = {1},
pages = {190--205},
doi = {10.1016/j.kint.2026.02.033}
}
EUVIMED